Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
That ends game one of the triple-header. Not too far away for the toss between Zimbabwe v Oman. We have already started our coverage of that game. We wrap up things here for this one. See you on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results